论文部分内容阅读
为了评价单用大剂量重组IL-2(rIL-2),对接受过强烈化疗的不同类型淋巴瘤是否有效,1989年4月至1991年6月对61例淋巴瘤进行Ⅱ期研究。 24例低度恶性非何杰金淋巴瘤对含有蒽环类的化疗方案耐药。23例中度或高度恶性非何杰金淋巴瘤,对初期化疗或补救治疗无效。7例何杰金病经过3个疗程的化疗无效或自体骨髓移植后复发。7例蕈样肉芽肿对化疗无效。所有病人在用药前进行体格检
To evaluate whether high-dose recombinant IL-2 alone (rIL-2) was effective for different types of lymphomas with aggressive chemotherapy, phase II studies of 61 patients with lymphoma from April 1989 to June 1991 were performed. Twenty-four patients with low-grade non-Hodgkin’s lymphoma were resistant to anthracycline-containing chemotherapy regimens. Twenty-three patients with moderate or high-grade non-Hodgkin’s lymphoma were ineffective with initial chemotherapy or salvage therapy. Seven cases of Hodgkin’s disease after 3 courses of chemotherapy or autologous bone marrow transplantation recurrence. Seven cases of mycosis fungoides chemotherapy ineffective. All patients undergo physical examination before medication